Prognostic factors for cases with metastatic renal cell carcinoma in the era of targeted medicine

International Journal of Urology

Volumn 16, Issue 11, 2009, Pages 855-861

  Neuzillet, Yann ^a   Culine, Stéphane ^b   Patard, Jean Jacques ^c  

^a FOCH HOSPITAL   (France)

^b University Hospital   (France)

^c PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Metastases; Prognostic factors; Renal cell carcinoma; TKI

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

CANCER IMMUNOTHERAPY; CANCER INVASION; DRUG MECHANISM; HUMAN; KIDNEY CARCINOMA; METASTASIS; NEPHRECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; RISK ASSESSMENT;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; MODELS, THEORETICAL; PROGNOSIS;

EID: 70350322136     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2009.02365.x     Document Type: Review

References (54)

1. Yang JC, Sherry RM, Steinberg SM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 2003 349 : 427 34.
2. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev. 2005 1 CD001425.
3. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 1999 17 : 2530 40.
4. Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. Published online 1 June 2009; DOI:10.1200/JCO.2008.20.1293.
5. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 2007 356 : 125 34.
6. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 2007 356 : 115 24.
7. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2008 370 : 2103 11.
8. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 2007 356 : 2271 81.
9. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008 372 : 449 56.
10. Desar IM, van Herpen CM, van Laarhoven HW, Barentsz JO, Oyen WJ, van der Graaf WT. Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev. 2009 35 : 309 21.
11. Patard JJ, Kim HL, Lam JS et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J. Clin. Oncol. 2004 22 : 3316 22.
12. Karakiewicz PI, Briganti A, Chun FK et al. Multi-institutional validation of a new renal cancer- specific survival nomogram. J. Clin. Oncol. 2007 25 : 1316 22.
13. Negrier S, Escudier B, Gomez F et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. Ann. Oncol. 2002 13 : 1460 8.
14. Liu Z, Lv J, Ding K, Fu Q, Cao Q, Wang F. Validation of the current prognostic models for nonmetastatic renal cell carcinoma after nephrectomy in Chinese population: a 15-year single center experience. Int. J. Urol. 2009 16 : 268 73.
15. May M, Brookman-Amissah S, Kendel F et al. Validation of a postoperative prognostic model consisting of tumor microvascular invasion, size, and grade to predict disease-free and cancer-specific survival of patients with surgically resected renal cell carcinoma. Int. J. Urol. 2009 16 : 616 21.
16. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001 358 : 966 70.
17. Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N. Engl. J. Med. 2001 345 : 1655 9.
18. Margulis V, Matin SF, Wood CG. Cytoreductive nephrectomy in metastatic renal cell carcinoma. Curr. Opin. Urol. 2008 18 : 474 80.
19. Eggener SE, Yossepowitch O, Kundu S, Motzer RJ, Russo P. Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. J. Urol. 2008 180 : 873 8.
20. Piltz S, Meimarakis G, Wichmann MW, Hatz R, Schildberg FW, Fuerst H. Long-term results after pulmonary resection of renal cell carcinoma metastases. Ann. Thorac Surg. 2002 73 : 1082 7.
21. Cerfolio RJ, Allen MS, Deschamps C et al. Pulmonary resection of metastatic renal cell carcinoma. Ann. Thorac Surg. 1994 57 : 339 44.
22. Pfannschmidt J, Hoffmann H, Muley T, Krysa S, Trainer C, Dienemann H. Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. Ann. Thorac Surg. 2002 74 : 1653 7.
23. Tanguay S, Swanson DA, Putnam JB Jr. Renal cell carcinoma metastatic to the lung: potential benefit in the combination of biological therapy and surgery. J. Urol. 1996 156 : 1586 9.
24. Kuruvath S, Naidu S, Bhattacharyya M, Benjamin JC, O'Donovan DG. Spinal metastasis from renal cell carcinoma, 31 years following nephrectomy - case report. Clin. Neuropathol. 2007 26 : 176 9.
25. Shuch B, La Rochelle JC, Klatte T et al. Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer 2008 113 : 1641 8.
26. Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. J. Clin. Oncol. 1998 16 : 2261 6.
27. Kierney PC, van Heerden JA, Segura JW, Weaver AL. Surgeon's role in the management of solitary renal cell carcinoma metastases occurring subsequent to initial curative nephrectomy: an institutional review. Ann. Surg. Oncol. 1994 1 : 345 52.
28. Rini BI, Campbell SC. The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. J. Urol. 2007 177 : 1978 8.
29. Upton MP, Parker RA, Youmans A, McDermott DF, Atkins MB. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J. Immunother. 2005 28 : 488 95.
30. Yamazaki K, Sakamoto M, Ohta T, Kanai Y, Ohki M, Hirohashi S. Overexpression of KIT in chromophobe renal cell carcinoma. Oncogene 2003 22 : 847 52.
31. Li Y, Guessous F, DiPierro C et al. Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy. Mol. Cancer Ther. 2009 8 : 376 85.
32. Hartman TR, Nicolas E, Klein-Szanto A et al. The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis. Oncogene 2009 28 : 1594 604.
33. Choueiri TK, Plantade A, Elson P et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J. Clin. Oncol. 2008 26 : 127 31.
34. Dutcher JP, de Souza P, McDermott D et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med. Oncol. 2009 26 : 202 9.
35. Mian BM, Bhadkamkar N, Slaton JW et al. Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J. Urol. 2002 167 : 65 70.
36. Golshayan AR, George S, Heng DY et al. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J. Clin. Oncol. 2009 27 : 235 41.
37. Karakiewicz PI, Trinh QD, de la Taille A et al. ECOG performance status 0 or 1 and symptom classification do not improve the ability to predict renal cell carcinoma-specific survival. Eur. Urol. 43 : 1023 9.
38. de Reijke TM, Bellmunt J, van Poppel H, Marreaud S, Aapro M. EORTC-GU group expert opinion on metastatic renal cell cancer. Eur. J. Cancer 2009 45 : 765 73.
39. Choueiri TK, Garcia JA, Elson P et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 2007 110 : 543 50.
40. Motzer RJ, Bukowski RM, Figlin RA et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 2008 113 : 1552 8.
41. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 2002 20 : 289 96.
42. Alamdari FI, Rasmuson T, Grankvist K, Ljungberg B. Angiogenesis and other markers for prediction of survival in metastatic renal cell carcinoma. Scand. J. Urol. Nephrol. 2007 41 : 5 9.
43. Deprimo SE, Bello CL, Smeraglia J et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J. Transl. Med. 2007 5 : 32.
44. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 2000 92 : 205 16.
45. Lassau N, Chami L, Benatsou B, Peronneau P, Roche A. Dynamic contrast-enhanced ultrasonography (DCE-US) with quantification of tumor perfusion: a new diagnostic tool to evaluate the early effects of antiangiogenic treatment. Eur. Radiol. 2007 17 : F89 98.
46. Stephen RM, Gillies RJ. Promise and progress for functional and molecular imaging of response to targeted therapies. Pharm. Res. 2007 24 : 1172 85.
47. Pantuck AJ, Seligson DB, Klatte T et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 2007 109 : 2257 67.
48. Choueiri TK, Vaziri SA, Jaeger E et al. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J. Urol. 2008 180 : 860 5.
49. Rini BI, Jaeger E, Weinberg V et al. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int. 2006 98 : 756 62.
50. Cho D, Signoretti S, Dabora S et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin. Genitourin. Cancer 2007 5 : 379 85.
51. Ljungberg B, Hanbury DC, Kuczyk MA et al. Renal cell carcinoma guideline. Eur. Urol. 2007 51 : 1502 10.
52. Patil S, Figlin RA, Hutson TE et al. Prognostic factors for overall survival with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 2009 27 : 244. Abstract 5042 (Meeting Abstracts).
53. Heng DY, Xie W, Regan MM et al. Prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF)-targeted agents: results from a large multicenter study. J. Clin. Oncol. 2009 27 : 244, Abstract 5041 (Meeting Abstracts).
54. Karakiewicz PI, Suardi N, Capitanio U et al. A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur. Urol. 2009 55 : 287 95.